Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Second Vaccination With GSK1247446A Influenza Vaccine
NCT00545025Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2007
- Primary completion
- Dec 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK1247446A in influenza (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms at 7 days, Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms at 7 days and 2 more. Started Oct 2007; status: completed.
02
Drugs
GSK1247446A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00545025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00545025.